This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Pot Stock That Hasn't Popped

NEW YORK (TheStreet) -- Puget Technologies (PUGE) has become the latest over the counter stock to radically shift its business plans and announce its intentions to enter the medical marijuana business.

However, unlike so many others, its stock hasn't popped yet. While shares were up 4.62% to 68 cents per share in mid-afternoon trading Friday, that is below their 50-day moving average of 80 cents per share.

According to its latest 10-K, filed Thursday after the close of trading, the Ft. Lauderdale, Fla.-based company, which "was incorporated in the State of Nevada on March 17, 2010 to engage in the development and operation of a business engaged in the distribution of luxury wool bedding products produced in Germany . . . redefined its business purpose to developing and selling leading edge consumer oriented products ready for rapid commercialization."

It acquired a company called B-29 Energy, Inc. on Sept. 2, 2013 whose "product lines under development include B-29 Energy Drinks and several medical marijuana products through its subsidiary, Cannabis Biotech."

Must Read: Furiex Pharma Diarrhea Drug Produces Solid Results in Pivotal Studies

Even though the acquisition occurred over five months ago, Thursday's filing appears to be the first time the company has mentioned the word "marijuana" in one of its regulatory filings, judging from a keyword search on Web site of the Securities and Exchange Commission.

Is Puget Technologies a legitimate business? Who knows? While the fact that it files with the SEC at all is a positive sign, that is scarcely a guarantee it has money-making potential. It had no revenue at all in the last fiscal year.

A call to Ronald Leyland, described in the 10-K as Puget Technologies' sole employee, wasn't returned.

Follow @dan_freed

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PUGE $0.01 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%
GOOG $750.26 0.00%
TSLA $231.61 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs